Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

INTRODUCTION: Dupilumab is an effective and safe medicine for the management of severe asthma. Due to its high cost, concerns are generated regarding its cost-effectiveness. This study aimed to estimate the cost-utility of dupilumab plus standard of care (SoC) versus SoC alone in children between 6 and 11 years old with severe asthma and eosinophilic phenotype. METHODS: A Markov-type model was developed to estimate costs and health outcomes of a simulated cohort of pediatric patients with persistent asthma treated over a 6-year period. To determine the robustness of the model deterministic and probabilistic sensitivity analyses were conducted. RESULTS: The quality-adjusted life-years (QALYs) per patient estimated were 0.85 with dupilumab and 0.84 with SoC. The total mean of discounted costs per patient per cycle were US$ 379 for dupilumab and US$ 19 for SoC. The incremental cost-effectiveness ratio estimated was $24 660 US$ per QALY CONCLUSION: Dupilumab is not cost-effective in Colombia in children between 6 and 11 years old with severe asthma and eosinophilic phenotype. Our evidence should motivate regulatory agencies to improve negotiations for new drugs with better information and evidence.

Original publication





Pediatr Pulmonol

Publication Date





2313 - 2319


health economics, healthcare, public health, Antibodies, Monoclonal, Humanized, Asthma, Cost-Benefit Analysis, Humans, Quality-Adjusted Life Years